Stephens raised the firm’s price target on ADC Therapeutics (ADCT) to $8 from $6 and keeps an Overweight rating on the shares. With data from LOTIS-5 and LOTIS-7 using Zylonta as a backbone therapy in combination for second-line diffuse large B-cell lymphoma, the firm views the second-line opportunity as becoming derisked, making the stock “highly underappreciated at these levels,” the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue